Teva's inhalers meet in Phase III asthma studies

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two multidose dry powder inhalers, fluticasone propionate/salmeterol MDPI formulation and fluticasone propionate MDPI formulation, met the primary endpoints of three Phase III trials to treat persistent asthma. The company plans to submit regulatory applications for the treatments in 2016.

Teva spokesperson Michelle Larkin told BioCentury that both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI had efficacy comparable to marketed products such as Advair salmeterol/fluticasone propionate and Flovent fluticasone propionate, but at lower doses. All doses of both products showed a greater benefit than placebo. ...